GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$40.32 USD
+0.06 (0.15%)
Updated Aug 12, 2024 04:00 PM ET
After-Market: $40.34 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$40.32 USD
+0.06 (0.15%)
Updated Aug 12, 2024 04:00 PM ET
After-Market: $40.34 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum B VGM
Zacks News
Is Celgene (CELG) Poised for a Beat This Earnings Season?
by Zacks Equity Research
Celgene Corporation (CELG) is expected to beat estimates once again on the back of strong performance of key drug Revlimid.
Is Gilead (GILD) Poised for a Beat This Earnings Season?
by Zacks Equity Research
A leader in the hepatitis C virus (HCV) space, Gilead Sciences' (GILD), is expected to beat expectations when it reports third-quarter results on Oct 26, after the market closes.
Foreign Stock Roundup SAP, Taiwan Semiconductor Earnings Impress, Ericsson Disappoints
by Swarup Gupta
Heightened geopolitical concerns, emanating from the Catalonia crisis and stalled Brexit negotiations weighed on Europe's stocks last week.
Novartis Reports Positive Results on Thrombocytopenia Drug
by Zacks Equity Research
Novartis AG (NVS) announced encouraging results on Revolade from the EXTEND study.
FDA Grants Priority Review for Exelixis' RCC Drug Cabomteyx
by Zacks Equity Research
Exelixis (EXEL) announced that the FDA has granted priority review to its supplemental New Drug Application (sNDA) for kidney cancer drug Cabomteyx.
Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada
by Zacks Equity Research
GlaxoSmithKline plc (GSK) announced that its vaccine Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged between 50 years or more.
Pfizer Considering Sale/Spin-Off of Consumer Healthcare Unit
by Zacks Equity Research
Pfizer (PFE) is exploring strategic alternatives for its Consumer Healthcare segment including a partial or a full separation through a spin-off, sale or other transaction.
Emergent Completes Acquisition of Anthrax Drug Raxibacumab
by Zacks Equity Research
Emergent BioSolutions Inc. (EBS) completes the acquisition of anthrax monoclonal antibody, raxibacumab, from GlaxoSmithkline.
Mylan (MYL) Gets FDA Approval for Generic Copaxone 40mg
by Zacks Equity Research
Mylan N.V. (MYL) gets a boost with the FDA's approval of the generic version of multiple sclerosis drug Copaxone.
Advanced Accelerator (AAAP) Cancer Therapy Approved in EU
by Zacks Equity Research
Advanced Accelerator Applications' (AAAP) Lutathera gets approval in Europe as its first radionuclide therapy for the treatment of tumors in the gut.
Agenus (AGEN) Remains Focused on Drug Development Programs
by Zacks Equity Research
Agenus' (AGEN) collaboration agreements provide a steady source of funds to boost pipeline development.
AstraZeneca's Bevespi Improves Lung Function in Phase III Study
by Zacks Equity Research
AstraZeneca plc (AZN) announced top-line data from a late stage study, which showed that its Bevespi Aerosphere led to a statistically significant improvement in lung function in patients with COPD.
J&J's Arthritis Candidate Sirukumab Denied FDA Approval
by Zacks Equity Research
J&J (JNJ) said that the FDA has denied approval to its investigational rheumatoid arthritis treatment, sirukumab for want of additional safety data.
Glaxo-Innoviva's Triple Combo Inhaler Positive in Phase III
by Zacks Equity Research
GlaxoSmithKline plc (GSK) along with partner Innoviva reports positive results from a phase III study, evaluating a single inhaler triple therapy in patients with COPD.
How GlaxoSmithKline (GSK) Stock Stands Out in a Strong Industry
by Zacks Equity Research
GlaxoSmithKline (GSK) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
Is GlaxoSmithKline plc (GSK) a Suitable Value Stock?
by Zacks Equity Research
GlaxoSmithKline is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.
Glaxo/Innoviva's Triple Combo Therapy Gets FDA Nod for COPD
by Zacks Equity Research
The FDA approves GlaxoSmithKline (GSK) and Innoviva's triple combination therapy, FF/UMEC/VI, for COPD. The drug will be accessed as Trelegy Ellipta in the U.S. market.
Glaxo's Triple Therapy COPD Inhaler Gets CHMP Nod in the EU
by Zacks Equity Research
Glaxo's (GSK) single inhaler triple therapy for the treatment of COPD in patients who are already being treated with a ICS/LAMA combination received a positive opinion from the CHMP in the EU.
Glaxo's Shingles Candidate Gets Positive FDA Committee Vote
by Zacks Equity Research
Glaxo (GSK) declared that an FDA advisory panel has unanimously voted recommending approval for its shingles vaccine candidate, Shingrix, in older patients.
Amgen/AstraZeneca Asthma Candidate Tezepelumab Shows Promise
by Zacks Equity Research
Amgen (AMGN) and AstraZeneca (AZN) announced promising data from a phase IIb study on tezepelumab, which reduced the rate of deterioration of asthma in patients with severe uncontrolled asthma.
Narasimhan to Replace Jimenez as Novartis (NVS) CEO in 2018
by Zacks Equity Research
Novartis AG (NVS) announced that its Chief Executive Officer (CEO), Joseph Jimenez will step down from his position in 2018.
Key FDA Regulatory Events to Watch Out for in Sep 2017
by Arpita Dutt
Will the FDA follow the recommendation of its advisory panel and give its nod to Amgen (AMGN) and Mylan's biosimilars?
Mylan and Otsuka Ink Agreement to Commercialize Deltyba
by Zacks Equity Research
Mylan (MYL) and Otsuka Pharmaceutical have entered into a license agreement to commercialize Deltyba in developing countries.
Why Have Mylan's (MYL) Shares Lost 19.4% So Far This Year?
by Zacks Equity Research
Shares of Mylan N.V. (MYL) have lost almost 19.4% in the year so far given the competitive pressure.
Are Glaxo's Successful New Drugs Enough to Drive Growth?
by Zacks Equity Research
Despite the success of new products, GlaxoSmithKline plc (GSK) believes that its overall performance has been weaker than it would have liked.